Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of 10 mcg HXP-GPOVac COVID-19 vaccine booster vs viral vector-based COVID-19 vaccines
TCTR20221026004Phase 3Unknown
- Sponsor
- Government Pharmaceutical Organization
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant NDV vectored vaccine for SARS-CoV-2 in coronavirus disease 2019 (COVID-19), sponsored by Government Pharmaceutical Organization. Status: unknown.
02
Drugs
recombinant NDV vectored vaccine for SARS-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20221026004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20221026004.